AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for previously untreated mantle cell lymphoma (MCL). It is approved in patients who are not eligible for autologous stem cell transplant. The approval by the European Commission was based on positive results from the ECHO Phase III trial, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!